Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AramarkARMK · Entity 3359 | Director | September 09, 2026 | September 10, 2026 |
| DEXCOM INCDXCM · Entity 3114 | Director | August 12, 2026 | August 13, 2026 |
| Merck & Co., Inc.MRK · Entity 2807 | Exe.VP & Pres.Con.Hlth.Care | May 09, 2014 | May 13, 2014 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Aramark
Report date September 09, 2026 · Filed September 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 35,896.827 |
Reported balance
After 2026-09-09 transaction · row 1
1 source rowRow 1 · 2026-09-09 · Grant · Acquired 75.532 · Balance 35,896.827 F1: Represents dividend equivalent rights in connection with the Issuer's quarterly dividend and accrued to the reporting person on deferred stock units held by the reporting person. These dividend equivalent rights vest on the same schedules as the underlying awards. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents dividend equivalent rights in connection with the Issuer's quarterly dividend and accrued to the reporting person on deferred stock units held by the reporting person. These dividend equivalent rights vest on the same schedules as the underlying awards.
DEXCOM INC
Report date August 12, 2026 · Filed August 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 29,570 |
Reported balance
After 2026-08-12 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-08-12 · Sale · Disposed 1,012 · Balance 29,570 F1: On August 14, 2025, Ms. Heller adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Ms. Heller. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2: Included in this number are 5,575 unvested restricted stock units which were granted on May 28, 2026 and will vest on the earlier of the one year anniversary of the grant date or the date of DexCom, Inc.'s 2027 Annual Meeting of Stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: On August 14, 2025, Ms. Heller adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Ms. Heller. The shares set forth above were sold pursuant to the 10b5-1 Plan.
F2: Included in this number are 5,575 unvested restricted stock units which were granted on May 28, 2026 and will vest on the earlier of the one year anniversary of the grant date or the date of DexCom, Inc.'s 2027 Annual Meeting of Stockholders.
Merck & Co., Inc.
Report date May 09, 2014 · Filed May 13, 2014
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $58.22 · Expires 2024-05-08 | Direct | 60,523 |
Reported balance
After 2014-05-09 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2014-05-09 · Grant · Acquired 60,523 · Balance 60,523 F2: The option vests in three equal annual installments beginning May 9, 2015. |
| Common StockSEC Table I · non-derivative | Direct | 35,473.7 |
Reported balance
Holding disclosure · report date 2014-05-09 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 35,473.7 F1: Holdings include shares acquired in dividend reinvestment transactions. |
Filing footnotes · ownership attribution and instrument terms
F1: Holdings include shares acquired in dividend reinvestment transactions.
F2: The option vests in three equal annual installments beginning May 9, 2015.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
INTEGRAL AD SCIENCE HOLDING CORP.
Report date December 23, 2025 · Filed December 23, 2025
Section 16 reporting ended · disclosed 2025-12-23. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $0.001 par valueSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2025-12-23 transaction · row 1
1 source rowRow 1 · 2025-12-23 · Disposition to issuer · Disposed 62,661 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of September 24, 2025 (the "Merger Agreement"), by and among the Issuer, Igloo Group Parent, Inc. ("Parent") and Igloo Group Acquisition Company, Inc. ("Merger Sub"), Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving as a wholly owned subsidiary of Parent. At the effective time of the Merger (the "Effective Time"), each issued and outstanding share of the Issuer's common stock, par value $0.001 per share ("Common Stock"), owned by the reporting person immediately prior to the Effective Time was automatically cancelled, extinguished and converted into the right to receive $10.30 per share in cash, without interest thereon (the "Per Share Price"). F2: The shares of Common Stock reported as disposed by the reporting person include 17,637 unvested restricted stock units ("Company RSUs") which were, at or immediately prior the Effective Time, fully vested, cancelled and converted into the right to receive, without interest, an amount in cash equal to the product of (i) the Per Share Price and (ii) the total number of shares of Common Stock subject to such Company RSUs. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger, dated as of September 24, 2025 (the "Merger Agreement"), by and among the Issuer, Igloo Group Parent, Inc. ("Parent") and Igloo Group Acquisition Company, Inc. ("Merger Sub"), Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving as a wholly owned subsidiary of Parent. At the effective time of the Merger (the "Effective Time"), each issued and outstanding share of the Issuer's common stock, par value $0.001 per share ("Common Stock"), owned by the reporting person immediately prior to the Effective Time was automatically cancelled, extinguished and converted into the right to receive $10.30 per share in cash, without interest thereon (the "Per Share Price").
F2: The shares of Common Stock reported as disposed by the reporting person include 17,637 unvested restricted stock units ("Company RSUs") which were, at or immediately prior the Effective Time, fully vested, cancelled and converted into the right to receive, without interest, an amount in cash equal to the product of (i) the Per Share Price and (ii) the total number of shares of Common Stock subject to such Company RSUs.
TECH DATA CORP
Report date June 30, 2020 · Filed July 02, 2020
Section 16 reporting ended · disclosed 2020-07-02. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2020-06-30 transaction · row 1
1 source rowRow 1 · 2020-06-30 · Disposition to issuer · Disposed 6,933 · Balance 0 F1: Tech Data Corporation (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement"), dated as of November 12, 2019 and amended on November 27, 2019 (the "Merger Agreement"), by and among the Company, Tiger Midco, LLC, a Delaware limited liability company ("Parent") and Tiger Merger Sub Co., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"). On June 30, 2020, Merger Sub merged with and into the Company, the separate corporate existence of Merger Sub ceased and the Company survived the merger as a direct wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, each share of Company common stock and each restricted stock unit subject to time-based vesting that was outstanding as of the closing of the merger was converted into the right to receive an amount in cash equal to $145.00, without interest and net of any required withholding of taxes. F2: Represents shares of Common Stock held by the Reporting Person. In connection with the closing of the transactions contemplated by the Merger Agreement, each share of Common Stock held by the Reporting Person as of the closing of the merger was converted into the right of the Reporting Person to receive a cash payment of $145.00, without interest and net of any required withholding of taxes. |
Filing footnotes · ownership attribution and instrument terms
F1: Tech Data Corporation (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement"), dated as of November 12, 2019 and amended on November 27, 2019 (the "Merger Agreement"), by and among the Company, Tiger Midco, LLC, a Delaware limited liability company ("Parent") and Tiger Merger Sub Co., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"). On June 30, 2020, Merger Sub merged with and into the Company, the separate corporate existence of Merger Sub ceased and the Company survived the merger as a direct wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, each share of Company common stock and each restricted stock unit subject to time-based vesting that was outstanding as of the closing of the merger was converted into the right to receive an amount in cash equal to $145.00, without interest and net of any required withholding of taxes.
F2: Represents shares of Common Stock held by the Reporting Person. In connection with the closing of the transactions contemplated by the Merger Agreement, each share of Common Stock held by the Reporting Person as of the closing of the merger was converted into the right of the Reporting Person to receive a cash payment of $145.00, without interest and net of any required withholding of taxes.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 30, 2020 Filed Jul 2, 2020 16:07 UTC | TECH DATA CORP TECD · Entity 148100 | Disposition to issuerCommon Stock | 6,933 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-020882 · form4.xml · nonDerivative · entry 1 Heller Bridgette P · CIK 0001485616 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Tech Data Corporation (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement"), dated as of November 12, 2019 and amended on November 27, 2019 (the "Merger Agreement"), by and among the Company, Tiger Midco, LLC, a Delaware limited liability company ("Parent") and Tiger Merger Sub Co., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"). On June 30, 2020, Merger Sub merged with and into the Company, the separate corporate existence of Merger Sub ceased and the Company survived the merger as a direct wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, each share of Company common stock and each restricted stock unit subject to time-based vesting that was outstanding as of the closing of the merger was converted into the right to receive an amount in cash equal to $145.00, without interest and net of any required withholding of taxes. F2 · shares: Represents shares of Common Stock held by the Reporting Person. In connection with the closing of the transactions contemplated by the Merger Agreement, each share of Common Stock held by the Reporting Person as of the closing of the merger was converted into the right of the Reporting Person to receive a cash payment of $145.00, without interest and net of any required withholding of taxes. F2 · price: Represents shares of Common Stock held by the Reporting Person. In connection with the closing of the transactions contemplated by the Merger Agreement, each share of Common Stock held by the Reporting Person as of the closing of the merger was converted into the right of the Reporting Person to receive a cash payment of $145.00, without interest and net of any required withholding of taxes. Read SEC document |
| May 22, 2020 Filed May 27, 2020 21:32 UTC | DEXCOM INC DXCM · Entity 3114 | GrantCommon Stock | 787 | $0.00 | $0.79 |
DisclosureSEC source: 0001093557-20-000160 · edgardoc.xml · nonDerivative · entry 1 Heller Bridgette P · CIK 0001485616 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,823 F1 · shares: The RSU Award was granted on May 22, 2020 and 100% of the RSU will vest on the earlier of the one year anniversary of the grant date or the date of DexCom Inc's 2021 Annual Meeting. Each share is represented by a restricted stock unit (RSU) that represents a contingent right to receive one share of DexCom, Inc. Common Stock upon settlement. F2 · balance_after: Included in this number are 3,823 unvested restricted stock units, 787 of which were granted on May 22, 2020 and shall vest on the earlier of the one year anniversary of the grant or the date of DexCom Inc's 2021 Annual Meeting and 3,036 of which were granted on September 13, 2019 and shall vest through September 13, 2022. Read SEC document |
| September 13, 2019 Filed Sep 17, 2019 22:45 UTC | DEXCOM INC DXCM · Entity 3114 | GrantCommon Stock | 3,036 | $0.00 | $3.04 |
DisclosureSEC source: 0001093557-19-000211 · wf-form4_156876030031149.xml · nonDerivative · entry 1 Heller Bridgette P · CIK 0001485616 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,036 F1 · shares: Share units are restricted and subject to vesting in three equal annual installments from the date of grant. Share units represent a contingent right to receive one share of DexCom, Inc. common stock. Read SEC document |
| June 05, 2019 Filed Jun 7, 2019 16:03 UTC | TECH DATA CORP TECD · Entity 148100 | GrantCommon Stock | 1,616 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-021117 · form4.xml · nonDerivative · entry 1 Heller Bridgette P · CIK 0001485616 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,933 F1 · shares: Restricted stock unit award which represents a contingent right to receive one share of Tech Data Corporation common stock for each vested unit. The restricted stock units vest 100% on the first grant date anniversary. F2 · balance_after: Direct: 4,437, unvested RSUs: 2,496 as of 6/6/19. Read SEC document |
| June 06, 2018 Filed Jun 8, 2018 07:07 UTC | TECH DATA CORP TECD · Entity 148100 | GrantCommon Stock | 1,454 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-020421 · form4.xml · nonDerivative · entry 1 Heller Bridgette P · CIK 0001485616 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,317 F1 · shares: Restricted stock unit award which represents a contigent right to receive one share of Tech Data Corporation common stock for each vested unit. The restricted stock units vest 100% on the first grant date anniversary. F2 · balance_after: As of June 7, 2018: Direct - 2,129; unvested RSUs - 3,188. Read SEC document |
| June 07, 2017 Filed Jun 8, 2017 16:11 UTC | TECH DATA CORP TECD · Entity 148100 | GrantCommon Stock | 1,275 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-020894 · form4.xml · nonDerivative · entry 1 Heller Bridgette P · CIK 0001485616 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,863 F1 · shares: Restricted stock unit award which represents a contigent right to receive one share of Tech Data Corporation common stock for each vested unit. The restricted stock units vest 100% on the first grant date anniversary. F2 · balance_after: Unvested RSUs. Read SEC document |
| November 29, 2016 Filed Nov 30, 2016 16:03 UTC | TECH DATA CORP TECD · Entity 148100 | GrantCommon Stock | 2,588 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-16-068654 · form4.xml · nonDerivative · entry 1 Heller Bridgette P · CIK 0001485616 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,588 F1 · shares: Restricted stock unit grant which represents a contigent right to receive one share of Tech Data Corporation common stock for each vested unit. The restricted stock units vest equally over three years on each anniversary date. F2 · balance_after: Unvested RSUs. Read SEC document |
| May 09, 2014 Filed May 13, 2014 19:53 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantStock Option (right to buy) · Derivative | 60,523 | $0.00 Strike: $58.22 | $0.00 |
DisclosureSEC source: 0001225208-14-012820 · doc4.xml · derivative · entry 2 Heller Bridgette P · CIK 0001485616 · Exe.VP & Pres.Con.Hlth.Care 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,523 Underlying: Common Stock · 60,523 shares Expires 2024-05-08 F2 · derivative.exercise_date: The option vests in three equal annual installments beginning May 9, 2015. Read SEC document |
| May 04, 2014 Filed May 6, 2014 20:02 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionRestricted Stock Unit · Derivative | 5,470 | $58.22 | $318,463.40 |
DisclosureSEC source: 0001225208-14-012268 · doc4.xml · derivative · entry 3 Heller Bridgette P · CIK 0001485616 · Exe.VP & Pres.Con.Hlth.Care 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,470 shares Expires 2014-05-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. Read SEC document |
| May 04, 2014 Filed May 6, 2014 20:02 UTC | Merck & Co., Inc. MRK · Entity 2807 | Tax withholdingCommon Stock | 2,837 | $58.22 | $165,170.14 |
DisclosureSEC source: 0001225208-14-012268 · doc4.xml · nonDerivative · entry 2 Heller Bridgette P · CIK 0001485616 · Exe.VP & Pres.Con.Hlth.Care 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,473.7 F1 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| May 04, 2014 Filed May 6, 2014 20:02 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 5,470 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-14-012268 · doc4.xml · nonDerivative · entry 1 Heller Bridgette P · CIK 0001485616 · Exe.VP & Pres.Con.Hlth.Care 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,310.7 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 24, 2014 Filed Feb 26, 2014 19:51 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantCommon Stock | 5,213 | $56.18 | $292,866.34 |
DisclosureSEC source: 0001225208-14-006332 · doc4.xml · nonDerivative · entry 1 Heller Bridgette P · CIK 0001485616 · Exe.VP & Pres.Con.Hlth.Care 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,799.704 F1 · shares: Distribution of net after tax shares of common stock on satisfaction of performance criteria for performance share units granted on 03/31/2011. Performance shares were paid out at 86 percent of target awards. F2 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| February 13, 2014 Filed Feb 14, 2014 16:17 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionStock Option (right to buy) · Derivative | 49,750 | $0.00 Strike: $36.56 | $0.00 |
DisclosureSEC source: 0001225208-14-004603 · doc4.xml · derivative · entry 3 Heller Bridgette P · CIK 0001485616 · Exe.VP & Pres.Con.Hlth.Care 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,877 Underlying: Common Stock · 49,750 shares Expires 2021-05-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 13, 2014 Filed Feb 14, 2014 16:17 UTC | Merck & Co., Inc. MRK · Entity 2807 | SaleCommon Stock | 43,870 | $55.04 | $2,414,569.70 |
DisclosureSEC source: 0001225208-14-004603 · doc4.xml · nonDerivative · entry 2 Heller Bridgette P · CIK 0001485616 · Exe.VP & Pres.Con.Hlth.Care 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,586.704 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $55.01 to $55.09, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. F2 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| February 13, 2014 Filed Feb 14, 2014 16:17 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 49,750 | $36.56 | $1,818,860.00 |
DisclosureSEC source: 0001225208-14-004603 · doc4.xml · nonDerivative · entry 1 Heller Bridgette P · CIK 0001485616 · Exe.VP & Pres.Con.Hlth.Care 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,456.704 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 13, 2013 Filed May 15, 2013 13:02 UTC | Merck & Co., Inc. MRK · Entity 2807 | SaleCommon Stock | 5,404 | $46.15 | $249,398.92 |
DisclosureSEC source: 0001225208-13-012296 · doc4.xml · nonDerivative · entry 1 Heller Bridgette P · CIK 0001485616 · Exe.VP & Pres.Con.Hlth.Care 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,706.704 F1 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| May 07, 2013 Filed May 8, 2013 23:29 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionStock Option (right to buy) · Derivative | 60,024 | $0.00 Strike: $33.49 | $0.00 |
DisclosureSEC source: 0001225208-13-011735 · doc4.xml · derivative · entry 7 Heller Bridgette P · CIK 0001485616 · Exe.VP & Pres.Con.Hlth.Care 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 60,024 shares Expires 2020-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 07, 2013 Filed May 8, 2013 23:29 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionRestricted Stock Unit · Derivative | 29,860 | $44.98 | $1,343,102.80 |
DisclosureSEC source: 0001225208-13-011735 · doc4.xml · derivative · entry 6 Heller Bridgette P · CIK 0001485616 · Exe.VP & Pres.Con.Hlth.Care 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 29,860 shares Expires 2013-05-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. Read SEC document |
| May 07, 2013 Filed May 8, 2013 23:29 UTC | Merck & Co., Inc. MRK · Entity 2807 | SaleCommon Stock | 54,532 | $45.08 | $2,458,466.16 |
DisclosureSEC source: 0001225208-13-011735 · doc4.xml · nonDerivative · entry 4 Heller Bridgette P · CIK 0001485616 · Exe.VP & Pres.Con.Hlth.Care 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,110.704 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.0500 to $45.1300, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. F2 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| May 07, 2013 Filed May 8, 2013 23:29 UTC | Merck & Co., Inc. MRK · Entity 2807 | Tax withholdingCommon Stock | 15,483 | $44.98 | $696,425.34 |
DisclosureSEC source: 0001225208-13-011735 · doc4.xml · nonDerivative · entry 3 Heller Bridgette P · CIK 0001485616 · Exe.VP & Pres.Con.Hlth.Care 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,642.704 Read SEC document |
| May 07, 2013 Filed May 8, 2013 23:29 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 29,860 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-13-011735 · doc4.xml · nonDerivative · entry 2 Heller Bridgette P · CIK 0001485616 · Exe.VP & Pres.Con.Hlth.Care 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,125.704 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 07, 2013 Filed May 8, 2013 23:29 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 60,024 | $33.49 | $2,010,203.76 |
DisclosureSEC source: 0001225208-13-011735 · doc4.xml · nonDerivative · entry 1 Heller Bridgette P · CIK 0001485616 · Exe.VP & Pres.Con.Hlth.Care 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,265.704 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 06, 2013 Filed May 8, 2013 23:29 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantStock Option (right to buy) · Derivative | 70,853 | $0.00 Strike: $44.98 | $0.00 |
DisclosureSEC source: 0001225208-13-011735 · doc4.xml · derivative · entry 5 Heller Bridgette P · CIK 0001485616 · Exe.VP & Pres.Con.Hlth.Care 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,853 Underlying: Common Stock · 70,853 shares Expires 2023-05-05 F3 · derivative.exercise_date: The option vests in three equal annual installments beginning May 6, 2014. Read SEC document |
| February 25, 2013 Filed Feb 27, 2013 22:50 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantCommon Stock | 7,174 | $42.52 | $305,038.48 |
DisclosureSEC source: 0001225208-13-005764 · doc4.xml · nonDerivative · entry 1 Heller Bridgette P · CIK 0001485616 · Exe.VP & Pres.Con.Hlth.Care 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,174 F1 · shares: Distribution of net after tax shares of common stock on satisfaction of performance criteria for performance share units granted on 3/31/2010. Performance shares were paid out at 107 percent of target awards. Read SEC document |
| May 02, 2012 Filed May 4, 2012 13:40 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantStock Option (right to buy) · Derivative | 80,439 | $0.00 Strike: $39.29 | $0.00 |
DisclosureSEC source: 0001225208-12-011186 · doc4.xml · derivative · entry 2 Heller Bridgette P · CIK 0001485616 · Exe.VP & Pres.Con.Hlth.Care 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,439 Underlying: Common Stock · 80,439 shares Expires 2022-05-01 F2 · derivative.exercise_date: The option vests in three equal annual installments beginning May 2, 2013. Read SEC document |
| May 02, 2012 Filed May 4, 2012 13:40 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantRestricted Stock Unit · Derivative | 5,599 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-12-011186 · doc4.xml · derivative · entry 1 Heller Bridgette P · CIK 0001485616 · Exe.VP & Pres.Con.Hlth.Care 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,599 Underlying: Common Stock · 5,599 shares Expires 2015-05-02 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. Read SEC document |
| May 04, 2011 Filed May 6, 2011 14:43 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantStock Option (right to buy) · Derivative | 74,627 | $0.00 Strike: $36.56 | $0.00 |
DisclosureSEC source: 0001225208-11-013364 · doc4.xml · derivative · entry 2 Heller Bridgette P · CIK 0001485616 · Exe.VP & Pres.Con.Hlth.Care 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,627 Underlying: Common Stock · 74,627 shares Expires 2021-05-03 F2 · derivative.exercise_date: The option vests in three equal annual installments beginning May 4, 2012. Read SEC document |
| May 04, 2011 Filed May 6, 2011 14:43 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantRestricted Stock Unit · Derivative | 5,470 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-11-013364 · doc4.xml · derivative · entry 1 Heller Bridgette P · CIK 0001485616 · Exe.VP & Pres.Con.Hlth.Care 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,470 Underlying: Common Stock · 5,470 shares Expires 2014-05-04 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. Read SEC document |
| May 07, 2010 Filed May 11, 2010 20:36 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantStock Option (right to buy) · Derivative | 60,024 | $0.00 Strike: $33.49 | $0.00 |
DisclosureSEC source: 0001225208-10-012621 · doc4.xml · derivative · entry 2 Heller Bridgette P · CIK 0001485616 · Exe.VP & Pres.Con.Hlth.Care 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,024 Underlying: Common Stock · 60,024 shares Expires 2020-05-06 F2 · derivative.exercise_date: The option vests in three equal annual installments beginning May 7, 2011. Read SEC document |
| May 07, 2010 Filed May 11, 2010 20:36 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantRestricted Stock Unit · Derivative | 29,860 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-10-012621 · doc4.xml · derivative · entry 1 Heller Bridgette P · CIK 0001485616 · Exe.VP & Pres.Con.Hlth.Care 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,860 Underlying: Common Stock · 29,860 shares Expires 2013-05-07 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.